Brokerages Set Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) PT at $48.40

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) have earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $48.40.

Several research analysts have recently commented on AAPG shares. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a research note on Tuesday. They set a “buy” rating and a $48.00 price target on the stock. Oppenheimer began coverage on shares of Ascentage Pharma Group International in a report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 price objective for the company. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, December 15th. BTIG Research initiated coverage on Ascentage Pharma Group International in a research report on Monday, November 10th. They issued a “buy” rating and a $50.00 price target for the company. Finally, Piper Sandler began coverage on Ascentage Pharma Group International in a research note on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target for the company.

Ascentage Pharma Group International Trading Down 0.9%

NASDAQ:AAPG opened at $27.05 on Wednesday. The stock’s 50 day moving average price is $29.68 and its 200 day moving average price is $35.81. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.53 and a current ratio of 1.54. Ascentage Pharma Group International has a 52 week low of $16.50 and a 52 week high of $48.45.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Ascentage Pharma Group International in the third quarter worth $96,000. ABC Arbitrage SA bought a new position in Ascentage Pharma Group International in the 3rd quarter worth $204,000. Chevy Chase Trust Holdings LLC acquired a new position in Ascentage Pharma Group International during the 2nd quarter worth $227,000. Citadel Advisors LLC acquired a new position in Ascentage Pharma Group International during the 3rd quarter worth $383,000. Finally, Hsbc Holdings PLC bought a new stake in Ascentage Pharma Group International during the second quarter valued at about $391,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.